Company news

Anavex Life Sciences Corp. news in 2024

Anavex Life Sciences Corp.'s news releases, calls and decks from 2024, newest first.

View company

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

December 22, 2024

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

December 22, 2024

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

December 15, 2024

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference

December 8, 2024

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

December 1, 2024

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA

November 25, 2024

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal

November 24, 2024

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

October 30, 2024

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

October 16, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

September 2, 2024

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

August 5, 2024

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

July 31, 2024

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

July 29, 2024

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

July 27, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

June 19, 2024

Anavex Life Sciences Announces Expansion of Leadership Team

May 21, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

May 13, 2024

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

May 8, 2024

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

May 1, 2024

Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

April 10, 2024

Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 24, 2024

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

March 17, 2024

Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference

February 25, 2024

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

February 6, 2024

Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024

January 31, 2024

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

January 23, 2024

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

January 15, 2024

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

January 7, 2024

Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Anavex Life Sciences Provides an Update on Rett Syndrome Program

January 1, 2024

Calls in 2024